ESSA Pharma Inc. (NASDAQ:EPIX – Get Free Report) (TSE:EPI) was the target of a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 1,010,000 shares, a growth of 14.4% from the June 15th total of 883,100 shares. Based on an average daily volume of 54,900 shares, the days-to-cover ratio is presently 18.4 days.
Analyst Ratings Changes
Separately, Oppenheimer restated an “outperform” rating and issued a $17.00 price target on shares of ESSA Pharma in a research note on Thursday, May 16th.
Get Our Latest Report on ESSA Pharma
Institutional Inflows and Outflows
ESSA Pharma Stock Performance
NASDAQ EPIX traded up $0.18 on Wednesday, hitting $5.70. 16,168 shares of the stock were exchanged, compared to its average volume of 101,701. The stock has a fifty day moving average price of $5.57 and a two-hundred day moving average price of $7.31. The firm has a market capitalization of $252.85 million, a P/E ratio of -9.05 and a beta of 1.82. ESSA Pharma has a 52-week low of $2.58 and a 52-week high of $11.67.
ESSA Pharma (NASDAQ:EPIX – Get Free Report) (TSE:EPI) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Sell-side analysts expect that ESSA Pharma will post -0.83 earnings per share for the current fiscal year.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Featured Stories
- Five stocks we like better than ESSA Pharma
- Consumer Staples Stocks, Explained
- Real Estate Stock Signals a Boom in Manufacturing Activity
- How Can Investors Benefit From After-Hours Trading
- This Medical Giant’s Stock Rebounds: A 15% Upside Is the Minimum
- 5 discounted opportunities for dividend growth investors
- Financial Giant’s Shares Soar on EPS Beat and Record Asset Levels
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.